Insmed (INSM) Net Equity Issued and Repurchased (2011 - 2025)
Insmed (INSM) posted quarterly Net Equity Issued and Repurchased of -$256000.0 for Q3 2025, down 100.07% year-over-year from $371.0 million in Q3 2024, and down 2033.33% quarter-over-quarter from -$12000.0 in Q4 2024.
Powered by 
Analysis
Insmed (INSM) Net Equity Issued and Repurchased (2011 - 2025) Analysis & Trends
Insmed's Net Equity Issued and Repurchased history runs 11 years deep, the most recent figure standing at -$256000.0 for Q3 2025.
- In Q3 2025, Net Equity Issued and Repurchased fell 100.07% year-over-year to -$256000.0; the TTM figure through Dec 2025 stood at $370.7 million (down 23.63% YoY), while the FY2025 annual figure was $823.3 million, down 24.06% from the prior year.
- Net Equity Issued and Repurchased for Q3 2025 stood at -$256000.0, down from -$12000.0 in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $371.0 million in Q3 2024, with the low at -$256000.0 in Q3 2025.
- The 4-year median for Net Equity Issued and Repurchased is $73.9 million (2022), against an average of $129.6 million.
- The sharpest annual moves came in 2023 and 2025: Net Equity Issued and Repurchased tumbled 55.77% in 2023, then sank 100.07% in 2025.
- Insmed's Net Equity Issued and Repurchased stood at $258.8 million in 2022, then sank by 55.77% to $114.5 million in 2023, then sank by 100.01% to -$12000.0 in 2024, then plunged by 2033.33% to -$256000.0 in 2025.
- Business Quant data shows INSM's Net Equity Issued and Repurchased at -$256000.0 in Q3 2025, -$12000.0 in Q4 2024, and $371.0 million in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -256,000.00 |
| Dec 31, 2024 | -12,000.00 |
| Sep 30, 2024 | 370.98 Mn |
| Dec 31, 2023 | 114.46 Mn |
| Dec 31, 2022 | 258.77 Mn |
| Sep 30, 2022 | 33.38 Mn |
| Dec 31, 2020 | 1,000.00 |
| Sep 30, 2020 | -47,000.00 |
| Sep 30, 2019 | -104,000.00 |
| Sep 30, 2017 | 377.70 Mn |
| Jun 30, 2015 | 42,000.00 |
| Dec 31, 2014 | 1.00 Mn |
| Dec 31, 2012 | -1,000.00 |
| Dec 31, 2011 | -32,000.00 |